Therapeutic angiogenesis: recent and future prospects of gene therapy in peripheral artery disease
Related Experiment Video
Updated: Apr 24, 2026

Preclinical Model of Hind Limb Ischemia in Diabetic Rabbits
Published on: June 2, 2019
Michiko Tanaka, Kikuko Taketomi, Yoshikazu Yonemitsu1
1Laboratory for Innovative Biotherapeutics, Graduate School of Pharmaceutical Sciences, Kyushu University, Room 601, Station II for Collaborative Research, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan. tmiciko@med.kyushu-u.ac.jp.
Abstract:
Peripheral artery disease (PAD) is a highly prevalent disease, which still has unmet medical needs. Therapeutic angiogenesis for PAD, achieved by gene therapy, has achieved promising results in preclinical studies and early-phase clinical trials, yet few late-phase clinical trials have been conducted or have not shown efficacy. This article provides an overview of the progression of angiogenesis research in gene therapy field as it applies to PAD. The focus of angiogenic growth factors and clinical trials is introduced as a frontier of therapeutic angiogenesis. The article also includes insights into future directions from bench to bedside.
Related Concept Videos
Peripheral Artery Disease III: Interprofessional Care
Regulation of Angiogenesis and Blood Supply
Mechanism of Angiogenesis
Gene Therapy
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...

